Free Technical Reports on Arrowhead Pharma and Three Additional Biotech Equities

Stock Research Monitor: ATRA, ATHX, and EARS

LONDON, UK / ACCESSWIRE / June 13, 2018 / If you want a free Stock Review on ARWR sign up now at www.wallstequities.com/registration. On Tuesday, June 12, 2018, the NASDAQ Composite and the S&P 500 edged 0.57% and 0.17% higher, respectively at the closing bell, while the Dow Jones Industrial Average stayed bearish, finishing marginally lower by 0.01%. US markets saw six out of nine sectors finishing the day in green and three in red. Taking into consideration yesterday’s market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), Atara Biotherapeutics Inc. (NASDAQ: ATRA), Athersys Inc. (NASDAQ: ATHX), and Auris Medical Holding AG (NASDAQ: EARS). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Arrowhead Pharmaceuticals

On Tuesday, shares in Pasadena, California headquartered Arrowhead Pharmaceuticals Inc. recorded a trading volume of 1.22 million shares. The stock ended at $11.35, rising 2.16% from the last trading session. The Company’s shares have gained 14.88% in the last month, 48.56% over the previous three months, and 618.35% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 35.56% and 103.87%, respectively. Furthermore, shares of Arrowhead Pharma, which develops medicines for the treatment of intractable diseases in the US, have a Relative Strength Index (RSI) of 71.89. Get the full research report on ARWR for free by clicking below at:

www.wallstequities.com/registration/?symbol=ARWR

Atara Biotherapeutics

South San Francisco, California headquartered Atara Biotherapeutics Inc.’s stock finished yesterday’s session 2.57% higher at $43.95. A total volume of 366,282 shares was traded. The Company’s shares have gained 235.50% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 1.99% and 53.99%, respectively. Furthermore, shares of Atara Biotherapeutics, which develops treatments for patients with cancer, autoimmune, and viral diseases in the US, have an RSI of 44.95. Today’s complimentary research report on ATRA is accessible at:

www.wallstequities.com/registration/?symbol=ATRA

Athersys

At the close of trading on Tuesday, shares in Cleveland, Ohio headquartered Athersys Inc. saw a rise of 0.61%, ending the day at $2.45. The stock recorded a trading volume of 957,967 shares, which was higher than its three months average volume of 832.21 thousand shares. The Company’s shares have advanced 18.03% in the last month, 33.42% in the previous three months, and 67.01% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 11.92% and 25.58%, respectively. Moreover, shares of Athersys, which focuses on the research and development activities in the field of regenerative medicine, have an RSI of 51.36. Register now for your free research document on ATHX at:

www.wallstequities.com/registration/?symbol=ATHX

Auris Medical Holding

Zug, Switzerland headquartered Auris Medical Holding AG’s shares ended the day flat at $1.18 with a total trading volume of 45,414 shares. The Company’s shares are trading below their 50-day moving average by 17.59%. Additionally, shares of Auris Medical, which focuses on the development of novel products for the treatment of inner ear disorders, have an RSI of 37.62. Click on the link below and see our free report EARS at:

www.wallstequities.com/registration/?symbol=EARS

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 502521